Effectiveness of treatment combining hepatic arterial chemoembolization and radiofrequency ablation and its influence on serum markers in patients with primary liver cancer / 中国现代医生

ABSTRACT

Objective To investigate the clinical effectiveness of treatment combining hepatic arterial chemoembolization (HACE) and radiofrequency ablation and its influence on serum markers in patients with primary liver cancer. Methods 50 patients with primary liver cancer in our hospital from January 2014 to January 2016 were selected and divided into observation group and control group. Patients in both of two groups were treated with HACE while patients in observation group were treated with additional radiofrequency ablation. Effectiveness of two groups was observed and compared. The levels of alpha fetoprotein (AFP), carbohydrate antigen 199 (CA199) and glutamyl transpeptidase (GGT) before and after treatment were detected. 2-year tumor-free survival and adverse reaction in two groups were observed. Results 4 weeks after treatment, levels of serum AFP, CA199 and GGT in two groups decreased significantly when compared with those before treatment(P＜0. 05 or P＜0. 0l) and those in observation group decreased more significantly(P＜0. 05). Total effective rate of treatment in observation group was higher than that in control group(P＜0. 05). The rate of 2-year tumor-free survival in observation group was higher than that in control group (P＜0. 05). The incidence of adverse reaction was not statistically different between two groups (P＞0. 05). Conclusion Treatment combining HACE and radiofrequency ablation in patients with primary live cancer was effective. It could reduce the levels of serum AFP, CA199 and GGT and improve the rate of 2-year tumor-free survival safely.